Hemostemix’s Pitch to Wall Street: ACP-01 Vascular Dementia Trial will Generate $5,365,000, Capture Data, as a Phase 1 Clinical Trial Read More
Hemostemix (PreCerv Inc.) Retains Chris McNorgan PhD to License NCP-01 to Neural Electrode Brain Implant Company Read More
Hemostemix Hiring 4 New Biotechnologists in Montreal and Appling for Grants to Fund up to 75% of 5-Year Costs Read More
